Log in

Relevant bibliographies by topics / B 20.5 UL 2012 B756

Contents

Journal articles

Academic literature on the topic 'B 20.5 UL 2012 B756'

Author: Grafiati

Published: 4 June 2021

Last updated: 14 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'B 20.5 UL 2012 B756.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "B 20.5 UL 2012 B756"

1

Beltran, Brady E., Erick Cotacallapa, and Jorge J. Castillo. "Survival and Clinicopathological Characteristics of EBV-Positive Diffuse Large B-Cell Lymphoma." Blood 120, no. 21 (2012): 1588. http://dx.doi.org/10.1182/blood.v120.21.1588.1588.

Full text

Abstract:

Abstract Abstract 1588 Background: EBV-positive diffuse large B-cell lymphoma (EBV+ DLBCL) of the elderly is a provisional entity included in the 2008 WHO Classification of Lymphomas. Diagnostic criteria include age >50 years, DLBCL morphology and EBV expression in lymphomatous cells. However, these criteria are evolving as several patients are <50 years and a specific cut-off for the percentage of EBV expression has not been defined. The goal of this retrospective study is to evaluate clinical and pathological characteristics of EBV+ DLBCL from Peruvian patients. Methods: Between Januar

APA, Harvard, Vancouver, ISO, and other styles

2

delMoral-Diez, Juan J., Elena Juventina Tuna-Aguilar, Alvaro Aguayo, Antonio Olivas-Martinez, and Gladys P. Agreda-Vasquez. "Prognosis in Patients with Human Immunodeficiency Virus Infection and Advanced Clinical Stage Classic Hodgkin's Lymphoma." Blood 134, Supplement_1 (2019): 5281. http://dx.doi.org/10.1182/blood-2019-123792.

Full text

Abstract:

Classic Hodgkin's lymphoma (cHL) represents 95% of all Hodgkin lymphomas, and is responsible of 0.5% of all cancer types (Siegel, Miller & Jemal, 2016). In HIV positive patients, the incidence of cHL is high (5-20 fold). The use of combination antiretroviral therapy (CART) and CD4 count >200 cells/uL appears to increase the risk; nonetheless, the risk for developing cHL in HIV infected patients remains high, regardless of CD4 count. The median patients' age of HIV-associated classic Hodgkin's lymphoma (HIV-cHL) ranges from 40 to 49 years old, slightly higher than the age observed in gen

APA, Harvard, Vancouver, ISO, and other styles

3

Mocikova, Heidi, Magdalena Klanova, Martin Spacek, et al. "Defining Criteria for Diagnosis of Occult Lymphomatous Involvement in Cerebrospinal Fluid." Blood 124, no. 21 (2014): 5412. http://dx.doi.org/10.1182/blood.v124.21.5412.5412.

Full text

Abstract:

Abstract Introduction: Currently, there is no consensus regarding diagnosis and treatment of occult lymphomatous menigeal involvement of cerebrospinal fluid (CSF) in patients with systemic non-Hodgkin lymphomas (NHL), especially in patients with minimal number of clonal cells detected by flow cytometry (FCM) or by cytology. Aim of the study: To describe a cohort of patients with occult lymphomatous involvement in cerebrospinal fluid including the diagnostic methods as well as management. Patients and methods: CSF at diagnosis of B-NHL was examined by FCM, cytology, biochemistry and microRNA an

APA, Harvard, Vancouver, ISO, and other styles

4

Advani, Anjali S., Anna Moseley, Michaela Liedtke, et al. "A Phase 1 Trial of Inotuzumab in Combination with CVP (Cyclophosphamide, Vincristine, Prednisone) for Relapsed/ Refractory CD22+ Acute Leukemia (SWOG 1312)." Blood 128, no. 22 (2016): 1634. http://dx.doi.org/10.1182/blood.v128.22.1634.1634.

Full text

Abstract:

Abstract The prognosis of patients (pts) with relapsed/ refractory acute lymphoblastic leukemia (ALL) remains poor and novel therapies are needed. The anti-CD22 immunoconjugate inotuzumab ozogamicin (INO) has demonstrated promising results in both phase 2 and 3 trials (Kantarjian et al. Lancet Oncology 2012; 13(4): 403-11). Pre-clinical studies have demonstrated superior anti-tumor activity when INO is co-administered with cyclophosphamide (C), vincristine (V), and prednisone (P). In this study, SWOG 1312, we assess the safety of INO in combination with CVP and determine the maximum tolerated

APA, Harvard, Vancouver, ISO, and other styles

5

Manotas, Karen, Jenny Jin, Cheryl Vinograd, et al. "Enhancing Therapy To Avoid Fetal Blood Sampling (FBS) In Antenatal Management Of Alloimmune Thrombocytopenia (AIT)." Blood 122, no. 21 (2013): 1072. http://dx.doi.org/10.1182/blood.v122.21.1072.1072.

Full text

Abstract:

Abstract Introduction Neonatal AIT (NAIT) is a potentially life-threatening, often severe thrombocytopenia caused by a parental human platelet antigen (HPA) incompatibility resulting in maternal alloantibodies attacking fetal platelets. NAIT affects approximately 1 in 1000 live births and may be accompanied by intracranial hemorrhage (ICH) in 10-20% of cases. Since there is no routine screening for NAIT, it is usually diagnosed after birth of the first affected thrombocytopenic fetus. Mothers of NAIT babies can be treated during subsequent affected pregnancies with IVIG and corticosteroids to

APA, Harvard, Vancouver, ISO, and other styles

6

Lemieux, Christopher, Imran Ahmad, Nadia M. Bambace, et al. "Safety and Efficacy of Autologous Hematopoietic Cell Transplantation for Elderly Patients with Lymphoma: Chemosensitive Disease Rather Than Age or Co-Morbidity Index Predicts Outcome." Blood 126, no. 23 (2015): 3171. http://dx.doi.org/10.1182/blood.v126.23.3171.3171.

Full text

Abstract:

Introduction: High dose chemotherapy (HDT) and autologous hematopoietic cell transplantation (AHCT) are considered standard of care as first line therapy in mantle cell lymphoma (Dreyling et al., 2005; Geisler et al., 2012) and in first line refractory and chemosensitive relapse Non-Hodgkin Lymphoma (NHL) (Philip et al., 1995) . The development of hematopoietic cell transplant comorbidity index (HCT-CI) (Sorror et al., 2009) for recipient selection and transplant risk evaluation have impacted on patient selection. Over the last decade, most transplant program have seen an increase in the media

APA, Harvard, Vancouver, ISO, and other styles

7

Thi Hong Nhung, Pham, Do Hanh Nguyen, Bui Thi Yen, Do Thi Le Hang, Vu Thi Thom, and Dinh Doan Long. "Genotyping ITS and matK regions of Hedera nepalensis K. Koch in Vietnam." VNU Journal of Science: Medical and Pharmaceutical Sciences 36, no. 3 (2020). http://dx.doi.org/10.25073/2588-1132/vnumps.4241.

Full text

Abstract:

This study develops procedures for cloning ITS and matK genes on six specimens in order to exploit and conserve the genetic resources of H. nepalensis and evaluate its genetic diversity based on molecular markers. The study methods include DNA extraction from dried leaf samples, amplification of ITS and matK regions using PCR, sequencing and comparing with the sequences on Genbank. The study results include a successfully-established process of cloning ITS and matK genes; successful amplification and sequencing of the ITS and matK regions. The results also show that four samples (N1-N4) were 1

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!